Header Logo

Connection

Alan Landay to CD4 Lymphocyte Count

Back to Details
This is a "connection" page, showing publications Alan Landay has written about CD4 Lymphocyte Count.
Alan Landay
Connection Strength
3.046
CD4 Lymphocyte Count
  1. Immune restoration following treatment. Abstract and Commentary. JAMA. 1997 Nov 12; 278(18):1538.
    View in: PubMed
    Score: 0.155
  2. Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 08 24; 30(13):2091-7.
    View in: PubMed
    Score: 0.143
  3. CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. PLoS One. 2015; 10(3):e0115019.
    View in: PubMed
    Score: 0.129
  4. Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses. 2015 Feb; 31(2):208-16.
    View in: PubMed
    Score: 0.126
  5. A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406.
    View in: PubMed
    Score: 0.124
  6. The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women. Viral Immunol. 2014 Feb; 27(1):20-5.
    View in: PubMed
    Score: 0.120
  7. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
    View in: PubMed
    Score: 0.093
  8. The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol. 2009 Mar; 130(3):298-303.
    View in: PubMed
    Score: 0.083
  9. A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S52-64.
    View in: PubMed
    Score: 0.078
  10. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
    View in: PubMed
    Score: 0.074
  11. Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol. 2005 Aug 01; 45(2):129-36.
    View in: PubMed
    Score: 0.065
  12. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.
    View in: PubMed
    Score: 0.061
  13. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 2004 Jan; 5(1):55-65.
    View in: PubMed
    Score: 0.059
  14. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14.
    View in: PubMed
    Score: 0.059
  15. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2003 Nov 15; 188(10):1444-54.
    View in: PubMed
    Score: 0.059
  16. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
    View in: PubMed
    Score: 0.058
  17. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003 Jul 15; 188(2):209-18.
    View in: PubMed
    Score: 0.057
  18. Elevated CD4 + T-cell glucose metabolism in HIV+ women with diabetes mellitus. AIDS. 2022 08 01; 36(10):1327-1336.
    View in: PubMed
    Score: 0.053
  19. The Hitchhiker Guide to CD4+ T-Cell Depletion in Lentiviral Infection. A Critical Review of the Dynamics of the CD4+ T Cells in SIV and HIV Infection. Front Immunol. 2021; 12:695674.
    View in: PubMed
    Score: 0.050
  20. Effects of cocaine and HIV on decision-making abilities. J Neurovirol. 2021 06; 27(3):422-433.
    View in: PubMed
    Score: 0.050
  21. A look at HIV immune research. Interview by Alan Huff. Res Initiat Treat Action. 2000 Sep; 6(3):30-3.
    View in: PubMed
    Score: 0.047
  22. T Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus. J Infect Dis. 2020 06 29; 222(2):252-262.
    View in: PubMed
    Score: 0.047
  23. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
    View in: PubMed
    Score: 0.046
  24. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.
    View in: PubMed
    Score: 0.046
  25. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan; 181(1):358-63.
    View in: PubMed
    Score: 0.045
  26. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019 09 13; 69(7):1165-1172.
    View in: PubMed
    Score: 0.044
  27. Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Lancet. 1999 Jan 16; 353(9148):211-2.
    View in: PubMed
    Score: 0.042
  28. Vitamin D does not modulate immune-mediated bone loss during ART initiation. Antivir Ther. 2019; 24(5):355-362.
    View in: PubMed
    Score: 0.042
  29. Polymorphism rs1385129 Within Glut1 Gene SLC2A1 Is Linked to Poor CD4+ T Cell Recovery in Antiretroviral-Treated HIV+ Individuals. Front Immunol. 2018; 9:900.
    View in: PubMed
    Score: 0.040
  30. Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease. AIDS. 2017 01 14; 31(2):199-205.
    View in: PubMed
    Score: 0.037
  31. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore). 2016 Aug; 95(33):e4483.
    View in: PubMed
    Score: 0.036
  32. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis. 1996 May; 173(5):1085-91.
    View in: PubMed
    Score: 0.035
  33. Standardization of absolute CD4+ lymphocyte counts across laboratories: an evaluation of the Ortho CytoronAbsolute flow cytometry system on normal donors. Cytometry. 1995 Sep 15; 22(3):200-10.
    View in: PubMed
    Score: 0.033
  34. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis. 2015 Apr 17; 15:190.
    View in: PubMed
    Score: 0.033
  35. Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry. 1995 Mar 15; 22(1):10-5.
    View in: PubMed
    Score: 0.032
  36. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr. 2014 Nov 01; 67(3):295-303.
    View in: PubMed
    Score: 0.031
  37. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014 Jul; 7(4):983-94.
    View in: PubMed
    Score: 0.030
  38. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
    View in: PubMed
    Score: 0.027
  39. Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis. 2012 Sep 01; 206(5):780-9.
    View in: PubMed
    Score: 0.027
  40. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
    View in: PubMed
    Score: 0.026
  41. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012; 7(1):e30306.
    View in: PubMed
    Score: 0.026
  42. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS. 2011 Sep 24; 25(15):1823-32.
    View in: PubMed
    Score: 0.025
  43. Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS. 2011 Jun 01; 25(9):1207-17.
    View in: PubMed
    Score: 0.025
  44. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91.
    View in: PubMed
    Score: 0.024
  45. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010 Mar 15; 201(6):823-34.
    View in: PubMed
    Score: 0.023
  46. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13; 23(5):605-10.
    View in: PubMed
    Score: 0.021
  47. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
    View in: PubMed
    Score: 0.021
  48. CD4 immunophenotyping in HIV infection. Nat Rev Microbiol. 2008 Nov; 6(11 Suppl):S7-15.
    View in: PubMed
    Score: 0.021
  49. PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol. 2008 Oct; 129(1):132-44.
    View in: PubMed
    Score: 0.020
  50. In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits. Clin Vaccine Immunol. 2008 Sep; 15(9):1398-409.
    View in: PubMed
    Score: 0.020
  51. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med. 2007 Mar 26; 167(6):597-605.
    View in: PubMed
    Score: 0.019
  52. Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS. 2007 Jan 30; 21(3):293-305.
    View in: PubMed
    Score: 0.018
  53. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
    View in: PubMed
    Score: 0.018
  54. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis. 2006 Oct 15; 194(8):1098-107.
    View in: PubMed
    Score: 0.018
  55. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006 Jul 01; 194(1):29-37.
    View in: PubMed
    Score: 0.018
  56. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006 May 01; 193(9):1202-10.
    View in: PubMed
    Score: 0.017
  57. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
    View in: PubMed
    Score: 0.017
  58. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004 Sep 24; 18(14):1953-6.
    View in: PubMed
    Score: 0.016
  59. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
    View in: PubMed
    Score: 0.015
  60. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8.
    View in: PubMed
    Score: 0.015
  61. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12972-7.
    View in: PubMed
    Score: 0.015
  62. Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.
    View in: PubMed
    Score: 0.014
  63. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003 Jan 15; 187(2):320-5.
    View in: PubMed
    Score: 0.014
  64. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
    View in: PubMed
    Score: 0.013
  65. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001 May 15; 97(10):2983-90.
    View in: PubMed
    Score: 0.012
  66. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000 Dec 01; 14(17):2635-42.
    View in: PubMed
    Score: 0.012
  67. T cell responses to recall antigens, alloantigen, and mitogen of HIV-infected patients receiving long-term combined antiretroviral therapy. AIDS Res Hum Retroviruses. 2000 Nov 20; 16(17):1887-93.
    View in: PubMed
    Score: 0.012
  68. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000 Sep 29; 14(14):2101-7.
    View in: PubMed
    Score: 0.012
  69. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
    View in: PubMed
    Score: 0.011
  70. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57.
    View in: PubMed
    Score: 0.011
  71. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999 Jul 30; 13(11):1295-303.
    View in: PubMed
    Score: 0.011
  72. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.
    View in: PubMed
    Score: 0.011
  73. Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 01; 19(4):408-12.
    View in: PubMed
    Score: 0.010
  74. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998 Jul 01; 102(1):79-87.
    View in: PubMed
    Score: 0.010
  75. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
    View in: PubMed
    Score: 0.010
  76. Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 01; 16(3):161-8.
    View in: PubMed
    Score: 0.010
  77. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997 Jul; 11(8):1013-21.
    View in: PubMed
    Score: 0.009
  78. Effect of zidovudine therapy on CD8+ T cell anti-HIV activity. Clin Immunol Immunopathol. 1994 Oct; 73(1):80-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.